Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Targeted Agents 100%
• Clinical Development 100%
• Epidermal Growth Factor Receptor 80%
• Platelet-derived Growth Factor Receptor (PDGFR) 40%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 40%
• Signaling Pathway 20%
• Growth Factors 20%
• Insulin-like 20%
• Chemotherapy 20%
• Patient Subgroups 20%
• Improved Outcomes 20%
• A1 Receptor 20%
• Optimal Treatment 20%
• Standard of Care 20%
• Insulin-like Growth Factor 1 Receptor (IGF1R) 20%
• Therapeutic Index 20%
• Treatment Dose 20%
• Novel Targeted Agents 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Platelet Derived Growth Factor Receptor 100%
• Epidermal Growth Factor Receptor 100%
• Vasculotropin Receptor 100%
• Chemotherapy 33%
• Therapeutic Window 33%
• Somatomedin C Receptor 33%

Medicine and Dentistry

• Vasculotropin Receptor 100%
• Platelet Derived Growth Factor Receptor 100%